[en] This presentation discusses the competition law issues raised by biosimilars. While many of the issues are similar to those raised by generics, the fact that, unlike generics, biosimilars are not exact copies of the original product means that the competition issues are slightly different as well. In essence, there seems to be more room for originators to pursue strategies designed to slow the entry of biosimilars into the market.
Disciplines :
European & international law Economic & commercial law
Author, co-author :
Hull, David ; Université de Liège - ULiège > Département de droit > Droit international et droit comparé de la concurrence
